Kyntra Bio, Inc.
KYNB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000921299
No open-market purchases or sales by Kyntra Bio, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $7.54M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Kyntra Bio, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 152 | 1 | 145 | −6 |
| Shares | 73.0M | 94.5K | 74.9M | +1.92M (+2.6%) |
| Value | $950.1M | $1.23M | $1.20B | +$250.2M (+26.4%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Kyntra Bio, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Logos Global Management LP | 525,000 | $8.41M | 0.99% |
| Woodline Partners LP | 391,107 | $6.27M | 0.09% |
| 5AM Venture Management, LLC | 225,583 | $3.61M | 0.97% |
| Integral Health Asset Management, LLC | 175,000 | $2.80M | 0.63% |
| State of New Jersey Common Pension Fund D | 166,617 | $2.67M | 0.01% |
| J. Goldman & Co LP | 113,693 | $1.82M | 0.13% |
| ExodusPoint Capital Management, LP | 110,859 | $1.78M | 0.03% |
| TD Asset Management Inc | 36,700 | $587.9K | 0.00% |
| Mirabella Financial Services LLP | 32,437 | $519.6K | 0.05% |
| Qube Research & Technologies Ltd | 25,497 | $408.5K | 0.00% |
| True North Advisors, LLC | 15,000 | $240.3K | 0.08% |
| WPWealth LLP | 13,846 | $221.8K | 0.12% |
| Franklin Street Advisors Inc | 10,000 | $160.0K | 0.02% |
| U.S. Capital Wealth Advisors, LLC | 3,393 | $54.4K | 0.00% |
| Altshuler Shaham Ltd | 1,722 | $27.6K | 0.00% |
| Romano Brothers and Company | 700 | $11.2K | 0.00% |
| Belpointe Asset Management LLC | 50 | $801 | 0.00% |
| Institutional & Family Asset Management, LLC | 24 | $384 | 0.00% |
Sold out (24)
Institutions that held Kyntra Bio, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
Not filed for Q4 2022 yet (1)
Institutions that held Kyntra Bio, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Eaton Vance Management | 94,478 | $1.23M |